RxDoctor Payments Data

Robert Waller, MD

Family Medicine · Marks, MSNPI 1821001041

Payments from drug & device makers

$431in general payments, 2019–2025

Across 17 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$125
  • Boehringer Ingelheim$65
  • Nestle Healthcare Nutrition Inc.$63
  • Electromed, Inc.$56
  • Avanir Pharmaceuticals, Inc.$36
  • Sunovion Pharmaceuticals Inc.$27
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$431 in reported general payments places this provider in the 45th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$615
Medicare patients
12
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$82,358
NuedextaDextromethorphan Hbr/Quinidine117$75,106
RexultiBrexpiprazole64$44,212
JardianceEmpagliflozin105$32,319
XareltoRivaroxaban94$26,644
Tresiba Flextouch U-100Insulin Degludec63$23,611
LinzessLinaclotide39$21,875
JanuviaSitagliptin Phosphate74$20,821
MyrbetriqMirabegron79$17,979
BrilintaTicagrelor67$15,032
Potassium Chloride375$14,795
TradjentaLinagliptin53$13,795
OzempicSemaglutide11$11,348
VeltassaPatiromer Calcium Sorbitex18$11,259
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$10,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$36$75,106117 claims
Boehringer IngelheimJardiance, Tradjenta$65$46,113158 claims
Johnson & JohnsonXarelto$12$26,64494 claims
Novo NordiskOzempic, Levemir$125$15,11131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Marks

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →